Evrysdi Powder, For Solution
NDC 50242-175
Product Information
Evrysdi (risdiplam) is a NDA-approved product labeled by Genentech, Inc.. This medication is typically used as a increased protein synthesis [pe]. It is supplied as a powder, for solution for oral administration. This product entry covers the primary NDC 50242-175 and its associated package configuration. This profile includes active and inactive ingredient UNII references and FDA labeling data.
Primary Identification
Clinical Specifications
Labeler & Regulatory Data
Marketing Timeline
Product Characteristics
Code Structure Chart
Product Details
What is NDC 50242-175?
What are the uses of this product?
What are Active Ingredients of this product?
- RISDIPLAM .75 mg/mL - small‐molecule SMN2 pre‐mRNA splicing modifier
Which are the associated UNII Codes?
The UNII codes for the active ingredients in this product are:
- RISDIPLAM (UNII: 76RS4S2ET1)
- RISDIPLAM (UNII: 76RS4S2ET1) (Active Moiety)
Which are the Inactive Ingredients associated UNII Codes?
The inactive ingredients are all the component of a medicinal product OTHER than the active ingredient(s). The acronym "UNII" stands for “Unique Ingredient Identifier” and is used to identify each inactive ingredient present in a product. The UNII codes for the inactive ingredients in this product are:
- MANNITOL (UNII: 3OWL53L36A)
- ISOMALT (UNII: S870P55O2W)
- MALTODEXTRIN (UNII: 7CVR7L4A2D)
- TARTARIC ACID (UNII: W4888I119H)
- SODIUM BENZOATE (UNII: OJ245FE5EU)
- POLYETHYLENE GLYCOL, UNSPECIFIED (UNII: 3WJQ0SDW1A)
- SUCRALOSE (UNII: 96K6UQ3ZD4)
- ASCORBIC ACID (UNII: PQ6CK8PD0R)
- EDETATE DISODIUM (UNII: 7FLD91C86K)
What is the NDC to RxNorm Crosswalk for this product?
- RxCUI: 2390940 - risdiplam 0.75 MG/mL Oral Solution
- RxCUI: 2390940 - risdiplam 0.75 MG/ML Oral Solution
- RxCUI: 2390940 - risdiplam 0.75 MG per ML Oral Solution
- RxCUI: 2390940 - risdiplam 60 MG per 80 ML Oral Solution
- RxCUI: 2390946 - Evrysdi 0.75 MG/mL Oral Solution
Which are the Pharmacologic Classes of this product?
- Increased Protein Synthesis - [PE] (Physiologic Effect)
- Multidrug and Toxin Extrusion Transporter 1 Inhibitors - [MoA] (Mechanism of Action)
- Multidrug and Toxin Extrusion Transporter 2 K Inhibitors - [MoA] (Mechanism of Action)
- Survival of Motor Neuron 2 Splicing Modifier - [EPC] (Established Pharmacologic Class)
- Survival of Motor Neuron 2 Splicing Modifiers - [MoA] (Mechanism of Action)
* Please review the full disclaimer at the bottom of this page.